Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | NPY4R | P50391 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14978852 | 1.00 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL23420078 | 1.00 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL27421382 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL23485287 | 0.96 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL23843840 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL23420151 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL27249189 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL14978945 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL28365735 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL21943125 | 0.95 | FAP (0.44) | FAPMAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661438-B2 | Purification of antibody drug conjugates using a sodium phosphate gradient | PFIZER, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220119545-A1 | CDCP1-TARGETED THERAPIES | BETH ISRAEL DEACONESS MEDICAL CENTER | 2022-04-21 | — | — | US | disclosed |
| WO-2021102332-A1 | TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| US-10668166-B2 | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment | TOXINVENT OU (EE) | 2020-06-02 | — | — | US | disclosed |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190269791-A1 | ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190048073-A1 | ANTI-GD3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | FAP 4182/4885MAP1LC3B 3751/4885SIRT2 4743/4885 |
| US-11661438-B2 | Purification of antibody drug conjugates using a sodium phosphate gradient | CD44, FCGR2A, FCGR1A | FAP 751/4885MAP1LC3B 1164/4885SIRT2 4645/4885 |
| US-20220119545-A1 | CDCP1-TARGETED THERAPIES | CD2BP2, CDC73, HSPBP1 | FAP 1215/4885MAP1LC3B 928/4885SIRT2 3948/4885 |
| US-20190269791-A1 | ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | FN1, EDNRB, EDF1 | FAP 1435/4885MAP1LC3B 582/4885SIRT2 4305/4885 |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885MAP1LC3B 451/4885SIRT2 2594/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | FAP 35/4885MAP1LC3B 1289/4885SIRT2 182/4885 |
| US-20190048073-A1 | ANTI-GD3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | NEU3, GOLGA3, GALNT3 | FAP 2692/4885MAP1LC3B 761/4885SIRT2 2600/4885 |
| US-10668166-B2 | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment | CD99, BCR, TOP2A | FAP 4571/4885MAP1LC3B 338/4885SIRT2 995/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | FAP 3829/4885MAP1LC3B 1500/4885SIRT2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.